PMID- 31843437
OWN - NLM
STAT- MEDLINE
DCOM- 20200805
LR  - 20200805
IS  - 1532-2653 (Electronic)
IS  - 0967-5868 (Linking)
VI  - 71
DP  - 2020 Jan
TI  - Short term real-world Fingolimod efficacy and safety in Emirati patients with 
      multiple sclerosis.
PG  - 39-42
LID - S0967-5868(19)31273-1 [pii]
LID - 10.1016/j.jocn.2019.11.010 [doi]
AB  - In clinical trials, Fingolimod was an efficacious and safe treatment for multiple 
      sclerosis (MS). Despite this, few studies have explored its real-world efficacy 
      and safety in the Middle East. The aim of this study was to describe our clinical 
      experience with Fingolimod at Cleveland Clinic Abu Dhabi in Emirati patients with 
      MS. We retrospectively collected clinical and brain and spinal cord MRI activity 
      over time in 30 Emirati MS patients [F/M = 22/8, mean (SD) disease duration at 
      treatment initiation = 3.3 (3.6) years, age at onset = 25.9 (6.9) years] who were 
      commenced on Fingolimod from 2015 and followed for 18 months. The proportion of 
      MS patients clinically and radiologically silent after Fingolimod initiation over 
      time was assessed together with annualized relapse rate (ARR) reduction and 
      adverse events (AEs) occurrence. 70% of MS patients who started Fingolimod were 
      naive. The baseline ARR [mean (SD; range)] was [1.2 (0.8; 0-4)] and 23.3% of MS 
      patients had Gadolinium enhancing lesions at baseline MRI. Overall, the ARR was 
      reduced by 72% and, relapses and MRI activity were found in only 24% and 38% of 
      MS patients respectively. Mild to moderate AEs were observed in 33% of MS 
      patients. No severe AEs were recorded. In Emirati MS patients, Fingolimod is safe 
      and efficacious as an early treatment choice.
CI  - Copyright (c) 2019 Elsevier Ltd. All rights reserved.
FAU - Ceccarelli, Antonia
AU  - Ceccarelli A
AD  - Neurological Institute, Cleveland Clinic Abu Dhabi, Sowwah Square, Al Maryah 
      Island, PO Box 112412, Abu Dhabi, United Arab Emirates. Electronic address: 
      ceccarelli.antonella@gmail.com.
FAU - Mifsud, Victoria
AU  - Mifsud V
AD  - Neurological Institute, Cleveland Clinic Abu Dhabi, Sowwah Square, Al Maryah 
      Island, PO Box 112412, Abu Dhabi, United Arab Emirates.
FAU - Abusamra, Eslam
AU  - Abusamra E
AD  - Neurological Institute, Cleveland Clinic Abu Dhabi, Sowwah Square, Al Maryah 
      Island, PO Box 112412, Abu Dhabi, United Arab Emirates.
FAU - Hussain, Syed Irteza
AU  - Hussain SI
AD  - Neurological Institute, Cleveland Clinic Abu Dhabi, Sowwah Square, Al Maryah 
      Island, PO Box 112412, Abu Dhabi, United Arab Emirates.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20191213
PL  - Scotland
TA  - J Clin Neurosci
JT  - Journal of clinical neuroscience : official journal of the Neurosurgical Society 
      of Australasia
JID - 9433352
RN  - 0 (Immunosuppressive Agents)
RN  - G926EC510T (Fingolimod Hydrochloride)
SB  - IM
MH  - Adult
MH  - Female
MH  - Fingolimod Hydrochloride/*therapeutic use
MH  - Humans
MH  - Immunosuppressive Agents/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Multiple Sclerosis/*drug therapy
MH  - Recurrence
MH  - Retrospective Studies
MH  - *Treatment Outcome
MH  - United Arab Emirates
OTO - NOTNLM
OT  - Efficacy
OT  - Emirati
OT  - Fingolimod
OT  - Multiple sclerosis
OT  - Real-world experience
OT  - Safety
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2019/12/18 06:00
MHDA- 2020/08/06 06:00
CRDT- 2019/12/18 06:00
PHST- 2019/07/01 00:00 [received]
PHST- 2019/10/07 00:00 [revised]
PHST- 2019/11/09 00:00 [accepted]
PHST- 2019/12/18 06:00 [pubmed]
PHST- 2020/08/06 06:00 [medline]
PHST- 2019/12/18 06:00 [entrez]
AID - S0967-5868(19)31273-1 [pii]
AID - 10.1016/j.jocn.2019.11.010 [doi]
PST - ppublish
SO  - J Clin Neurosci. 2020 Jan;71:39-42. doi: 10.1016/j.jocn.2019.11.010. Epub 2019 
      Dec 13.